Cytos Biotechnology says allergy drug trials succeed

Cytos Biotechnology AG said trials of a treatment for allergic diseases such as dermatitis had been successful.

Cytos said a phase IIa study involving the use of CYT003-QbG10 on 36 patients with mild to moderate atopic dermatitis had shown it was safe and generally well tolerated.

Cytos chief executive Wolfgang Renner said the company is still identifying the best treatment parameters for the drug's application as a monotherapy, although it had shown strong efficacy in conjunction with a specific allergen in patients with house dust mite allergy.

'This monotherapy has achieved first promising results in grass pollen and also house dust mite allergy,' Renner said.
For the latter indication, we are now testing higher doses of the product candidate. Based on the outcome of these studies, we will then also consider the path forward in atopic dermatitis.'

souce:www.forbes.com